Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | FLI1 | Q01543 | 1/20 | 0.31 |
| ▸ | EWSR1 | Q01844 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5482232 | 0.83 | MAPT (0.33) | CES1ALDH1A1 | |
| SCHEMBL5477636 | 0.83 | CNR1 (0.40) | CES1 | |
| SCHEMBL5480076 | 0.76 | MAPT (0.43) | CES1ALDH1A1HSD17B10CYP3A4 | |
| SCHEMBL5482277 | 0.76 | SMN1; SMN2 (0.43) | ALDH1A1TSHRCYP3A4TDP1 | |
| SCHEMBL5479391 | 0.76 | CES1 (0.34) | CES1HPGD | |
| SCHEMBL5478235 | 0.68 | HTT (0.46) | CES1ALDH1A1TSHRALOX15 | |
| SCHEMBL5475160 | 0.66 | POLB (0.44) | CES1ALDH1A1TSHRALOX15 | |
| SCHEMBL5475401 | 0.66 | HTT (0.43) | CES1ALDH1A1TSHRALOX15 | |
| SCHEMBL5474643 | 0.66 | CNR1 (0.61) | HTR6CES1ALDH1A1TSHRALOX15 | |
| SCHEMBL5474437 | 0.63 | CNR1 (0.57) | HTR6CES1ALDH1A1TSHRALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070299102-A1 | Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer | TOPO TARGET A/S (DK) | 2007-12-27 | — | — | US | claimed |
| US-20070299102-A1 | Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer | TOPO TARGET A/S (DK) | 2007-12-27 | — | — | US | disclosed |
| EP-1734951-A2 | DIPHENYL-INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | TopoTarget A/S (DK) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005097107-A2 | DIPHENYL - INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | TOPOTARGET A/S (DK) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299102-A1 | Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer | MTOR, RICTOR, CDK4 | HTR6 639/4885CES1 4132/4885FLI1 538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.